Cargando…

Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19

Detalles Bibliográficos
Autores principales:	Patoulias, Dimitrios, Papadopoulos, Christodoulos, Doumas, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135494/ https://www.ncbi.nlm.nih.gov/pubmed/35644695 http://dx.doi.org/10.1016/j.amjcard.2022.04.038

Ejemplares similares

Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Colchicine for the prevention of COVID-19 “hard” outcomes: All that glitters is not gold
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review
por: Papadopoulos, Christodoulos, et al.
Publicado: (2020)

Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Time to assess the effects of sodium–glucose co‐transporter‐2 inhibitors on the ‘forgotten' right ventricle?
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
por: Patoulias, D., et al.
Publicado: (2022)

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

COVID-19: The Waterloo of governments, healthcare systems, and large health organizations
por: Doumas, Michael, et al.
Publicado: (2020)

Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
por: Dimosiari, Athina, et al.
Publicado: (2023)

The Impact of Metabolic Syndrome Components on Erectile Function in Patients with Type 2 Diabetes
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

Efficacy and Safety of Antiplatelet Agents for Adult Patients With Ischemic Moyamoya Disease
por: Ye, Fei, et al.
Publicado: (2021)

COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?
por: Doumas, Michael, et al.
Publicado: (2020)

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Metaanálisis para evaluar el riesgo de infecciones respiratorias y síndrome de distrés respiratorio del adulto con los agonistas del receptor del péptido similar al glucagón tipo 1 en los ensayos de seguridad cardiovascular: consecuencias útiles para la pandemia de COVID-19
por: Patoulias, D., et al.
Publicado: (2022)

Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials
por: Dimosiari, Athina, et al.
Publicado: (2022)

Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison
por: Gagne, Joshua J, et al.
Publicado: (2013)

Effect of COVID-19 on endothelial function evaluated with flow-mediated dilation: another prognostic marker? A meta-analysis of observational studies
por: Dimosiari, Athina, et al.
Publicado: (2022)

The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis
por: Wang, Qi, et al.
Publicado: (2020)

Efficacy and Safety of Proton Pump Inhibitors in Patients With Coronary Artery Diseases Receiving Oral Antiplatelet Agents and/or Anticoagulants: A Systematic Review and Meta-Analysis
por: Shang, Yao-Sheng, et al.
Publicado: (2022)

EFFECT OF ANTICOAGULATION AND ANTIPLATELET AGENTS ON HYPERCOAGULABILITY STATES IN PATIENTS WITH COVID-19
por: UR, JEANNIE, et al.
Publicado: (2021)

Meta-analysis addressing the impact of sodium-glucose Co-transporter-2 inhibitors on the risk for atrial fibrillation among individuals with heart failure with preserved ejection fraction
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Antiplatelet/anticoagulant agents for preventing thrombosis events in patients with severe COVID-19: A protocol for systematic review and meta-analysis
por: Li, Yiwei, et al.
Publicado: (2020)

The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Safety of dental extractions in patients on dual antiplatelet therapy – a meta-analysis
por: Zabojszcz, Michał, et al.
Publicado: (2019)

Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis
por: De Carlo, Marco, et al.
Publicado: (2021)

Efficacy and Safety of Antiplatelet Therapy Plus Xa Factor Inhibitors in Patients with Coronary Heart Disease: A Meta-Analysis
por: Chen, Hongsen, et al.
Publicado: (2019)

Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis
por: Katsanos, Konstantinos, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v75dloju43ini48pg61ib45jv0